Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

BMC Cancer

Rémi Marty²  Stéphane Roze²  Xavier Bresse³  Nathalie Largeron³  Jayne Smith-Palmer¹ 

[1] Ossian Health Economics and Communications, Basel, Switzerland

[2] HEVA, 186 Avenue Thiers, Lyon, 69006, France

[3] SPMSD SNC, Lyon, France

关键词: Cervical cancer;    HPV-related disease;    Genital warts;    HPV-related cancer;    Vaccination;    Human papillomavirus;   

Others  :  1079980
DOI  :  10.1186/1471-2407-13-10

 received in 2012-05-24, accepted in 2012-12-28,  发布年份 2013

【 摘 要 】

Background

HPV is related to a number of cancer types, causing a considerable burden in both genders in Europe. Female vaccination programs can substantially reduce the incidence of HPV-related diseases in women and, to some extent, men through herd immunity. The objective was to estimate the incremental benefit of vaccinating boys and girls using the quadrivalent HPV vaccine in Europe versus girls-only vaccination. Incremental benefits in terms of reduction in the incidence of HPV 6, 11, 16 and 18-related diseases (including cervical, vaginal, vulvar, anal, penile, and head and neck carcinomas and genital warts) were assessed.

Methods

The analysis was performed using a model constructed in Microsoft®Excel, based on a previously-published dynamic transmission model of HPV vaccination and published European epidemiological data on incidence of HPV-related diseases. The incremental benefits of vaccinating 12-year old girls and boys versus girls-only vaccination was assessed (70% vaccine coverage were assumed for both). Sensitivity analyses around vaccine coverage and duration of protection were performed.

Results

Compared with screening alone, girls-only vaccination led to 84% reduction in HPV 16/18-related carcinomas in females and a 61% reduction in males. Vaccination of girls and boys led to a 90% reduction in HPV 16/18-related carcinomas in females and 86% reduction in males versus screening alone. Relative to a girls-only program, vaccination of girls and boys led to a reduction in female and male HPV-related carcinomas of 40% and 65%, respectively and a reduction in the incidence of HPV 6/11-related genital warts of 58% for females and 71% for males versus girls-only vaccination.

Conclusions

In Europe, the vaccination of 12-year old boys and girls against HPV 6, 11, 16 and 18 would be associated with substantial additional clinical benefits in terms of reduced incidence of HPV-related genital warts and carcinomas versus girls-only vaccination. The incremental benefits of adding boys vaccination are highly dependent on coverage in girls. Therefore, further analyses should be performed taking into account the country-specific situation. In addition to clinical benefits, substantial economic benefits are also anticipated and warrant further investigation as do the social and ethical implications of including boys in vaccination programs.

【 授权许可】

   
2013 Marty et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsague X: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012, 12:30. BioMed Central Full Text
• [2]De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-36.
• [3]Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS: Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010, 2:15. BioMed Central Full Text
• [4]Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S: Human papillomavirus prevalence and type distribution in penile carcinoma. J ClinPathol 2009, 62:870-8.
• [5]Borget I, Abramowitz L, Mathevet P: Economic burden of HPV-related cancers in France. Vaccine 2011, 29:5245-9.
• [6]Robinson D, Coupland V, Møller H: An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009, 100:527-31.
• [7]Mehanna H, Jones TM, Gregoire V, Ang KK: Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010, 340:c1439.
• [8]Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ahrlund-Richter S, Marklund L, Romanitan M, Lindquist D, Ramqvist T, Lindholm J, Sparén P, Ye W, Dahlstrand H, Munck-Wikland E, Dalianis T: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009, 125:362-366.
• [9]Dempsey AF, Koutsky LA, Golden M: Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sex Transm Dis 2007, 34:503-7.
• [10]Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
• [11]Lacey CJ, Lowndes CM, Shah KV: Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl 3):35-41.
• [12]Hoy T, Singhal PK, Willey VJ, Insinga RP: Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin. 2009, 25:2343-51.
• [13]Monsonégo J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Rémy V: Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynecol Obstet Fertil 2007, 35:107-13.
• [14]Raymakers AJ, Sadatsafavi M, Marra F, Marra CA: Economic and humanistic burden of external genital warts. PharmacoEconomics 2012, 30:1-16.
• [15]Castellsagué X, Cohet C, Puig-Tintoré LM, Acebes LO, Salinas J, San Martin M, Breitscheidel L, Rémy V: Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health 2009, 19(1):106-10.
• [16]Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New Engl J Med 2011, 364:401-11.
• [17]Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-67.
• [18]Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K: The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011, 29:9112-22.
• [19]Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC: Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011, 204:372-6.
• [20]Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, Panatto D, Gasparini R, Boccalini S: An overview on the implementation of HPV vaccination in Europe. Hum Vaccin 2011, 7(Suppl):128-35.
• [21]Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J: Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 2011, 8(12):e1001147.
• [22]Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13:28-41.
• [23]Dasbach EJ, Insinga RP, Elbasha EH: The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008, 115:947-56.
• [24]Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent humanpapillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
• [25]Anttila A, Ronco G, Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE): Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009, 45:2685-708.
• [26]Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE: The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29:8443-50.